September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Size and Growth of Geographic Atrophy During 5 Years of Follow Up in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Author Affiliations & Notes
  • Juan E Grunwald
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Perelman Sch of Med, Philadelphia, Pennsylvania, United States
  • Maxwell Pistilli
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Perelman Sch of Med, Philadelphia, Pennsylvania, United States
  • Ebenezer Daniel
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Perelman Sch of Med, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Perelman Sch of Med, Philadelphia, Pennsylvania, United States
  • Glenn J Jaffe
    Ophthalmology, Duke University, Raleigh, North Carolina, United States
  • Stuart L Fine
    Ophthalmology, University of Colorado, Aurora, Colorado, United States
  • Daniel F Martin
    Cole Eye Institute, Cleveland, Ohio, United States
  • Maureen G Maguire
    Ophthal-Scheie Eye Inst, Univ of Pennsylvania, Perelman Sch of Med, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Juan Grunwald, None; Maxwell Pistilli, None; Ebenezer Daniel, None; Gui-Shuang Ying, None; Glenn Jaffe, Alcon/Novartis (C), Genentec/Roche (C), Heidelberg Engineering (C), Neurotech (C); Stuart Fine, None; Daniel Martin, None; Maureen Maguire, Genentec (C)
  • Footnotes
    Support  Cooperative agreements U10EY023530, U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and R21EY023689 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Juan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, Gui-Shuang Ying, Glenn J Jaffe, Stuart L Fine, Daniel F Martin, Maureen G Maguire; Size and Growth of Geographic Atrophy During 5 Years of Follow Up in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To quantify the size and growth rate of geographic atrophy (GA) during 5 years of follow up among patients in the CATT.

Methods : 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to a 2-year monthly or PRN injection dosing regimen, or monthly injections for 1 year and PRN injections the following year. Patients were released from protocol treatment at 2 years and recalled for examination at approximately 5 years.
Two graders masked to treatment measured total GA size in digital color photographs (CP) and fluorescein angiograms (FA) taken at baseline, Years 1, 2 and 5 using Image J; differences were adjudicated. Annual change in the square root of the total area of GA was the measure of growth. Multivariate linear mixed models including baseline demographic, treatment, and ocular characteristics on CP/FA and OCT as candidate risk factors were used to estimate adjusted growth rates, standard errors (SE), and 95% confidence intervals.

Results : Among 529 patients followed for 5 years with gradable photographs, 214 (40.5%) had GA at Year 5, and 112 had at least 2 GA measurements at different time points allowing the estimation of growth rates.

Mean area of prevalent GA at baseline was 1.93 (0.36, SE) mm2. Mean area of incident GA at the time of first detection at Years 1, 2, and 5 were 1.89 (0.40), 2.86 (0.95) and 7.09 (0.85) mm2. Although GA size increased over time by a mean of 0.29 (0.02) mm/year, the GA growth rate generally decreased from years 1 to 5 (Table 1).

Multivariate analysis results (Table 2) showed that predominantly classic lesions were associated with higher growth rate than occult only lesions (0.38 vs. 0.24 mm/year, p=0.04). Eyes without sub-RPE fluid had higher GA growth than eyes with sub-RPE fluid away from the fovea or subfoveal (0.35, 0.31 and 0.21 mm/year respectively p=0.02). There was no significant difference in GA growth between GA associated with the CNV lesion and GA that was outside the CNV lesion (0.28 vs. 0.30 mm/year, p=0.91), and between the two drugs (p=0.12) and three dosing regimens (p=0.89) that patients received during the first two years of the study (Table 2).

Conclusions : In this cohort of patients followed for approximately 5 years higher GA growth was observed in eyes with predominantly classic lesions and eyes with no sub-RPE fluid at baseline.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×